Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
Neuro Central,
BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company…
BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company…
The unexpected finding that EphA3 is highly expressed in the tumor microenvironment could lead to a new treatment for blood…
An international team of scientists has shown that an antibody against the protein EphA3, found in the micro-environment of…
EphA3 illustration (Protein Data Bank/Wikimedia Commons) 14 August 2014. Researchers in the U.S. and Australia identified an…